Is tigecycline's manufacturing more standardized in generics?

How does tigecycline compare to other antibiotics in terms of manufacturing standardization?

Tigecycline is a glycylcycline antibiotic used to treat complicated skin and soft tissue infections, intra-abdominal infections, and community-acquired pneumonia. It belongs to a class of drugs that has fewer manufacturers because its molecular complexity requires advanced fermentation and purification processes. Fewer companies produce it as a generic compared to simpler antibiotics such as amoxicillin or ciprofloxacin.

What standards must generic manufacturers meet for tigecycline?

Generic manufacturers must follow current Good Manufacturing Practice (cGMP) regulations enforced by the FDA. These rules require consistent batch-to-batch quality, impurity limits, and stability profiles. The complexity of tigecycline's synthesis and purification steps makes it harder to achieve consistent quality than for many other antibiotics.

Why do some generic versions of tigecycline show variation?

Some generic versions show variation in impurity profiles and dissolution rates. This occurs because manufacturers differ in their synthesis routes, purification methods, and raw material sources. Studies have found that several generic versions meet official USP specifications but have higher levels of epimer impurities than the innovator product.

When does tigecycline's patent expire?

Tigecycline's patent network is complex. The primary patent expired in 2015, but additional patents covering formulation and manufacturing methods extended exclusivity until 2019. The earliest generic launches occurred in 2018–2019 under the FDA's Paragraph IV certification pathway. Multiple companies now produce active pharmaceutical ingredient (API) and finished dosage forms.

What companies make tigecycline generics?

Several companies produce tigecycline generics. The active pharmaceutical ingredient comes from Indian and Chinese manufacturers such as Hetero, Alembic, and Pontoteka. Finished products are marketed by U.S. companies such as Pfizer (innovator), Mylan, and MABxcience. Finished products are also marketed by U.S. companies such as Pfizer (innovator), M.S. and MABxcience.